OxyContin / PurdueAtlas

Evidence

12 cited sources · both-sides readings on each item

• In never-before-seen video, Purdue’s Richard Sackler defends OxyContin marketing

  statnews.com · secondary

  • Pos A · The STAT and ProPublica report is read as showing Richard Sackler defending OxyContin marketing under oath; skeptical readings treat such materials as already reflected in conventional public-record summaries of the claim set, pending fuller sourced research.“Richard Sackler defends OxyContin marketing”
  • Pos B · The STAT and ProPublica report is read as showing Richard Sackler defending OxyContin marketing under oath; affirming readings treat such materials as under-weighted in mainstream summaries of the claim set, pending fuller sourced research.“Richard Sackler defends OxyContin marketing”
• Purdue and OxyContin: A timeline

  latimes.com · secondary

  • Pos A · The LA Times timeline is treated as a conventional public chronology already available in mainstream coverage; skeptical readings cite it as consistent with the view that stronger OxyContin/Purdue claim-sets remain overstated until research supplies fuller comparative sources.“Purdue and OxyContin: A timeline”
  • Pos B · The LA Times timeline is treated as a partial public chronology that affirming readings cite as still under-accounted relative to the full claim-set; they read it as underscoring the need for research to supply sources before the shell is settled.“Purdue and OxyContin: A timeline”
• OxyContin maker Purdue Pharma to plead guilty to three criminal charges – report

  theguardian.com · secondary

  • Pos A · Coverage of Purdue’s planned guilty plea and multibillion-dollar settlement is treated as already prominent in the public record, so skeptical readings cast the broader claim set as potentially overstated until additional sources are supplied and compared.“will plead guilty to three federal criminal charges”
  • Pos B · Coverage of Purdue’s planned guilty plea and multibillion-dollar settlement is treated as marking accountability still under-weighted in mainstream summaries, so affirming readings cast the broader claim set as potentially under-accounted until additional sources are supplied and compared.“will plead guilty to three federal criminal charges”
• OxyContin maker Purdue Pharma to plead to 3 criminal charges

  postandcourier.com · secondary

  • Pos A · The plea and multi-billion settlement are read as already prominent in the public record; skeptical readings treat the OxyContin/Purdue claim set as overstated relative to that coverage until research supplies fuller sources for this shell.“will plead guilty to three federal criminal charges”
  • Pos B · The plea and multi-billion settlement are read as still thin in mainstream summaries; affirming readings treat the OxyContin/Purdue claim set as under-accounted relative to that record until research supplies fuller sources for this shell.“settlement of more than $8 billion”
• Purdue, Oxycontin, and the Opioid War

  youtube.com · tertiary

  • Pos A · Materials titled along these lines are read as inviting conventional caution that OxyContin and Purdue accounts may be overstated pending fuller sourced comparison to the public record.“Purdue, Oxycontin, and the Opioid War”
  • Pos B · Materials titled along these lines are read as inviting affirming caution that OxyContin and Purdue accounts may be under-accounted pending fuller sourced comparison to mainstream summaries.“Purdue, Oxycontin, and the Opioid War”
• Purdue Pharma Knew Oxycontin Was Being Abused Since The Late '90s

  techtimes.com · secondary

  • Pos A · The TechTimes summary of a leaked Justice Department report is read as restating contested early-awareness claims; skeptical readings treat the “OxyContin / Purdue” set as potentially overstated relative to the compared public record until research supplies fuller primary sources and this shell is approved.“Purdue Pharma knew all along Oxycontin was being abused”
  • Pos B · The TechTimes summary of a leaked Justice Department report is cited as indicating internal notes on abuse soon after launch; affirming readings treat the “OxyContin / Purdue” set as under-accounted for in mainstream summaries until research supplies fuller primary sources and this shell is approved.“aware of the significant abuse of Oxycontin”
• OxyContin Maker Purdue Pharma To Plead Guilty As Part Of $8 Billion Settlement | NBC Nightly News

  youtube.com · tertiary

  • Pos A · Public materials are read as placing Purdue’s guilty plea and large settlement already on the compared record, so broader OxyContin claim sets are treated as overstated until research supplies fuller sources.“Purdue Pharma To Plead Guilty As Part Of”
  • Pos B · Public materials are read as placing Purdue’s guilty plea and large settlement as markers of major responsibility, so broader OxyContin claim sets are treated as under-accounted for until research supplies fuller sources.“deeply regrets and accepts responsibility”
• The history of OxyContin, told through unsealed Purdue documents

  statnews.com · secondary

  • Pos A · Public materials such as the STAT timeline are read as documenting internal Purdue launch and marketing records already widely discussed; the Sackler email is treated as forceful commercial rhetoric that skeptical readings say does not by itself settle how far the claim set exceeds the compared public record, so further sourced research remains required before the shell is treated as settled.“feared as a tiger with claws, teeth and balls”
  • Pos B · Public materials such as the STAT timeline are read as surfacing unsealed Purdue strategy and role details affirming readings say mainstream summaries still under-account; the Sackler email is cited as illustrating the intensity of internal posture around OxyContin’s push, so further sourced research remains required before the shell is treated as settled. The competing reading remains available for comparison from the same public materials.“feared as a tiger with claws, teeth and balls”
• OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

  apnews.com · secondary

  • Pos A · The AP report is treated as showing criminal penalties and planned dissolution already present in the public record, so skeptical readings cite the sentence as consistent with conventional accounts rather than requiring expansion of the claim set.“ordered to pay $225 million in a criminal case”
  • Pos B · The AP report is treated as showing criminal penalties and planned dissolution that affirming readings cite as still partial relative to wider impacts, so the sentence is read as supporting further accounting beyond mainstream summaries.“OxyContin maker Purdue Pharma set to dissolve”
• Behind Purdue Pharma’s marketing of OxyContin

  youtube.com · tertiary

  • Pos A · Skeptical readings treat the YouTube item on Purdue’s OxyContin marketing as a partial public-record pointer that still needs fuller sourcing before the claim set is read as settled or as outweighing compared mainstream summaries.“Behind Purdue Pharma’s marketing of OxyContin”
  • Pos B · Affirming readings treat the same YouTube item on Purdue’s OxyContin marketing as a cited marker that mainstream digests under-account the marketing dispute, while still requiring research sources before the shell is treated as settled.“Behind Purdue Pharma’s marketing of OxyContin”
• nytimes.com

  nytimes.com · secondary

  • Pos A · The cited report is read as one prosecutorial account of early abuse awareness and marketing continuity; skeptical readings treat the OxyContin/Purdue claim set as still overstated relative to the compared public record until research supplies fuller sources for this shell.“knew about “significant” abuse of OxyContin”
  • Pos B · The cited report is treated as documenting early abuse awareness and marketing continuity; affirming readings treat the OxyContin/Purdue claim set as still under-accounted for in mainstream summaries until research supplies fuller sources for this shell. The competing reading remains available for comparison from the same public materials.“knew about “significant” abuse of OxyContin”
• OxyContin maker Purdue Pharma set to dissolve after judge approves sentence

  washingtonexaminer.com · secondary

  • Pos A · Public materials on the judge-approved sentence and planned dissolution are read as aligning with an already documented legal close-out; skeptical readings treat the claim set as potentially overstated until fuller comparative sources are supplied for this shell.“Purdue Pharma set to dissolve after judge approves”
  • Pos B · Public materials on the judge-approved sentence and planned dissolution are read as underscoring liability still lightly weighed in brief summaries; affirming readings treat the claim set as potentially under-accounted until fuller comparative sources are supplied for this shell.“pay over $5 billion in criminal penalties”